Rhode Island House Bill H7628

Rhode Island 2026 Regular Session

• Introduced: 2/11/26
• Refer: 2/11/26

Caption

Requires health insurers to develop a plan to provide adequate coverage, of and access to, a broad spectrum of pain management service.

Impact

The enactment of HB7628 is expected to have significant implications for existing state laws governing health insurance practices, particularly in relation to pain management. By ensuring that health insurance providers include a broader selection of pain management options, the bill directly influences how insurers must approach coverage of pain treatments starting January 1, 2027. Consequently, this could lead to altered practices within the health care system, impacting how patient care is administered and financed. Additionally, it emphasizes the role of the health insurance commissioner in reviewing and approving pain management plans, which may improve oversight of insurance practices within the state.

Summary

House Bill 7628 aims to enhance access to pain management services by requiring health insurers to develop comprehensive coverage plans. Specifically, it mandates that every individual or group health insurance contract that provides prescription coverage, which is issued or renewed in Rhode Island, must include a wide array of pain management services. This includes not only non-opioid medications but also non-medication alternatives to effectively manage pain, with an emphasis on reducing reliance on potentially addictive opioid medications. The bill is geared towards better addressing the rising concerns of the opioid crisis by promoting wider use of non-narcotic pain management options.

Contention

Notable points of contention around HB7628 stem from concerns regarding the adequacy of the proposed pain management services and the extent of the commissioner's regulatory power over insurance providers. Opponents may argue that while the intent to limit opioid prescriptions is commendable, the lack of specific guidelines or a clear mechanism for assessing the effectiveness of these alternative treatments could undermine the bill’s objectives. Furthermore, discussions around implementation timelines and the potential costs to health insurers could lead to debates in legislative committees, as stakeholders assess the bill's feasibility and overall impact on both patients and insurance systems.